Figures & data
Figure 1. Possible strategy to reduce the risk of recurrent/late-onset viral disease using adoptive T cell therapy. (A) Patients with sufficient immune reconstitution are at low risk of recurrent/late-onset viral disease. (B) Patients with insufficient immune reconstitution are at high risk of recurrent/late-onset viral disease. (C) In patients with insufficient immune reconstitution, adoptive T cell therapy might reduce the risk of recurrent/late-onset viral disease.
Figure 2. Possible clinical trial design incorporating adoptive T cell therapy as preemptive therapy or prophylaxis of infectious diseases at high risk of them
